5Suppliers
4Customers
1Debt Items
20Related Chains

BioNTech SE Suppliers

TickerNameConfidenceEvidence
EVAX Evaxion A/S 72% Reciprocal relationship from EVAX graph: drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pres…
MGNX MacroGenics, Inc. 72% Reciprocal relationship from MGNX graph: n exclusive option to license worldwide rights to the research program, upon achievement of a pre-defined preclinical milestone. HIV DART Molecules We conduct…
MRVI Maravai LifeSciences Holdings, Inc. 72% Reciprocal relationship from MRVI graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from MRVI graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from MRVI g…
MTNB Matinas BioPharma Holdings, Inc. 72% Reciprocal relationship from MTNB graph: . The lease impairment charges were included in the impairment charges of other assets line in the consolidated statement of operations and comprehensive loss…
SMMT Summit Therapeutics Inc. 72% Reciprocal relationship from SMMT graph: commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”).…

BioNTech SE Customers

TickerNameConfidenceEvidence
EVAX Evaxion A/S 72% Reciprocal relationship from EVAX graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from EVAX graph: ing income in the mid double-digit range. We have initiated a Phase 2 trial,…
MGNX MacroGenics, Inc. 72% Reciprocal relationship from MGNX graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from MGNX graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from MGNX g…
MTNB Matinas BioPharma Holdings, Inc. 72% Reciprocal relationship from MTNB graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from MTNB graph: contractors associated with Chemistry and Manufacturing Controls (CMC), pre-…
SMMT Summit Therapeutics Inc. 72% Reciprocal relationship from SMMT graph: commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”).…

BioNTech SE Debt Obligations

InstrumentDescriptionConfidenceEvidence
BNTX-DEBT Debt stack $352.2M 90% Market cache reports total debt of $352.2M.

BioNTech SE Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for BioNTech SE.

BioNTech SE Ownership

HolderNameConfidenceEvidence
BNTX-OWNER-T-ROWE-PRICE-INVESTMENT-MANAGEME T. Rowe Price Investment Management, Inc. 90% 13F overlay lists T. Rowe Price Investment Management, Inc. as top holder; 274 tracked holders.

BioNTech SE Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
SNYNF Sanofi 100.00 2
PYXS Pyxis Oncology, Inc. 100.00 2
BORAY Bora Pharmaceuticals Co., Ltd. 100.00 2
SMMT Summit Therapeutics Inc. 100.00 2 ['customer', 'supplier']
MRK Merck & Co., Inc. 100.00 2
MRVI Maravai LifeSciences Holdings, Inc. 100.00 1 ['supplier']
AZN AstraZeneca PLC 100.00 2
ECO Okeanis Eco Tankers Corp. 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
ARTV Artiva Biotherapeutics, Inc. 100.00 2
CMPX Compass Therapeutics, Inc. 100.00 2
CLLS Cellectis S.A. 100.00 2
EVAX Evaxion A/S 100.00 1 ['customer', 'supplier']
GILD Gilead Sciences, Inc. 100.00 2
GSK GSK plc 100.00 2
GNMSF Genmab A/S 100.00 2
INBX Inhibrx Biosciences, Inc. 100.00 2
INCY Incyte Corporation 100.00 2
CAH Cardinal Health, Inc. 100.00 2
MTNB Matinas BioPharma Holdings, Inc. 100.00 1 ['customer', 'supplier']